Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

edivoxetine

- PMLiVE

Healthware Group report on depression care in Italy highlights need for digital therapeutics

Mental health disorders are the fifth leading cause of disability adjusted life years in Italy

- PMLiVE

Mental Health Awareness Week

This year the theme of Mental Health Awareness Week is loneliness, focusing on the impact of it on our mental health and the practical steps we can take to address...

Mednet

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies

Supporting Mental Health During a Global Pandemic

Sam Duboc, Chair & CEO of MindBeacon, explores virtual care and telehealth for treating depression, anxiety, addiction, and other conditions; mental health issues brought on by COVID-19; and how to...

Impetus Digital

- PMLiVE

Biogen signs $3.1bn deal with Sage for potential depression therapies

Zuranolone already has a breakthrough therapy designation from the US FDA

- PMLiVE

Acadia’s Nuplazid misses the mark in major depressive disorder trial

Company's efforts to extend drug's reach fall flat

Impetus Digital Fireside Chat with with Jon Sockell, Co-Founder/COO of Limbix

Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,...

Impetus Digital

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links